Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase III Open Label Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face

Authors not listed

Biolab Sanus Farmaceutica · 2009

Stem-cell exhaustion Human Randomized controlled trial

Abstract

The purpose of this study is to determinate whether Xeomin® (Botulinum toxin Type A) is safe, effective and tolerable in woman aged 30 to 50 years old for treatment of mild, moderate or severe expression lines (wrinkles) in the upper third of the face. The main outcome was the change in appearance of the wrinkles two weeks (visit 3) after product application as compared with baseline assessment.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-05-29 MST

Cite this

APA

Anonymous. (2009). Phase III Open Label Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face. <em>Biolab Sanus Farmaceutica</em>. https://clinicaltrials.gov/study/NCT00986570

Vancouver

Anonymous. Phase III Open Label Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face. Biolab Sanus Farmaceutica. 2009.

BibTeX

@misc{anon2009PhaseI, title = {Phase III Open Label Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face}, author = {Anonymous}, journal = {Biolab Sanus Farmaceutica}, year = {2009}, }